Soligenix’s ThermoVax platform shows efficacy in vaccine stability

Soligenix (SNGX) announced a publication describing the extended stability of ebolavirus vaccines using its ThermoVax platform. Bivalent and trivalent vaccines, constructed from antigens against Zaire ebolavirus, Sudan ebolavirus and Marburg marburgvirus and the CoVaccine HT antigen, were formulated in a single vial and subjected to long-term storage at up to 40 degrees C. After two years of storage, all vaccines were unchanged and had equivalent potency as when initially manufactured. The manuscript has been accepted for publication and is available online in Vaccine.